bioRxiv Science⌕ Search

Biology subjects

Geremew, D.

Publications and source records attributed to Geremew, D..

2 recordsLinked to original sources

Development of a novel murine model of in-stent neoatherosclerosis

ObjectiveIn-stent neoatherosclerosis is a phenomenon of percutaneous coronary intervention with stenting. Whilst similar to de novo atherosclerosis, it develops rapidly over 1-5 years rather than over a lifetime. No preclinical small animal models exist that allow full elucidation of neoatherosclerosis biology and future treatments. The aim of this study was to establish and validate a novel murine model of in-stent neoatherosclerosis. Approach and ResultsMurine stainless-steel stents (2.5 x 0.7 mm) were deployed into donor descending aortas of atherosclerosis-prone apolipoprotein (Apo)e-/- mice, then carotid-interposition grafted into Apoe-/- recipients. Mice (n=6-8/group) received chow or a high cholesterol diet (HCD) for 7- or 28-days post-surgery. Multimodal intravascular imaging, simultaneously combining optical coherence tomography (OCT, plaque burden) and fluorescence for indocyanine green (ICG, plaque instability), visualized in-stent neoatherosclerosis across the entire length of the stented site. Histological analyses revealed that stented vessels from mice fed HCD had neointimas with prominent lipid cores and an elevated CD68+ macrophage content, similar to human neoatherosclerosis. Mice fed chow post-stenting had distinctly different neointimas that were smooth muscle cell rich, resembling neointimal hyperplasia. Consistent with this, flow cytometry revealed a higher content of monocytes/macrophages and dendritic cells in stented aortas from mice fed HCD than in non-stented aortas. ConclusionWe have developed and validated the first murine model that replicates the unique characteristics of human in-stent neoatherosclerosis. This project has implications for exploring the mechanisms that promote neoatherosclerosis and testing targeted new therapies. RESEARCH PERSPECTIVEO_ST_ABSWhat Is New?C_ST_ABSO_LIWe have developed and validated a novel murine model of in-stent neoatherosclerosis, presenting a new platform that will facilitate the discovery of novel mechanistic targets of in-stent neoatherosclerosis and preventative therapies. C_LIO_LIThis model develops lesions with a similar morphology to human in-stent neoatherosclerosis and distinct to in-stent neointimal hyperplasia, with higher extracellular lipid and macrophage content and proportionately less smooth muscle cells. C_LIO_LIWe show a first-time visualization of murine in-stent neoatherosclerosis using bimodal intravascular imaging with simultaneous capture of structural information (optical coherence tomography, plaque burden) and the distribution of areas of plaque instability (high-sensitivity fluorescence, indocyanine green) within the plaque. C_LI What new question does this study raise?O_LIHow can the utility of this novel model be maximized as a platform for discovering novel agents that prevent in-stent neoatherosclerosis? C_LI What question should be addressed next?O_LIAre there unique mechanisms of in-stent neoatherosclerosis, distinct to de novo atherosclerosis, that can be specifically targeted to prevent disease and ultimately increase stent performance? C_LI

cell biology↗

Evidence that poor HAART adherence has a great impact on HIV/AIDS treatment failure more than severity of illness and opportunity of infection in Ethiopia: Systematic review and meta-analysis

BackgroundThe pooled burden of HIV treatment failure and its associated factors in Ethiopian context is required to provide evidence towards renewed ambitious future goal.\n\nMethodsPubMed, Web of Science, Scopus, Google Scholar, and Ethiopian Universities (University of Gondar and Addis Ababa University) online repository library were used to get the research articles. I-squared statistics was used to see heterogeneity. Publication bias was checked by Eggers regression test. A meta-analysis using the DerSimonian-Laird random-effects model was employed to estimate the overall prevalence of treatment failure. Subgroup analyses based on the geographical location of the study, age of study population, type of treatment failure, and study design were conducted to see variation in outcomes. The sensitivity analysis was also employed to see whether an outlier result found in the included studies.\n\nResultsOverall HIV treatment failure found to be 15.9% (95% CI: 11.6%-20.1%). HIV treatment failure was 10.2% (6.9%-13.6%) using immunological definition, 5.6% (95% CI: 2.9%-8.3%) using virological definition, and 6.3% (4.6%-8.0%) using clinical definition. Poor HAART adherence (AOR= 8.5; 95% CI: 4.1-12.8), severity of illness (as measured by WHO clinical stage III/IV (AOR=1.9; 95% CI: 1.3-2.6), and presence of opportunistic infections (AOR=1.8; 95% CI: 1.2-2.4) were significantly associated with HIV treatment failure.\n\nConclusionsHIV treatment failure in Ethiopia found to be high and differed by adherence level, severity of illness, and presence of opportunistic infection. HIV intervention programs, such as behavioral intervention is required to sustain HIV treatment adherence and improve treatment success as a result.\n\nProtocol RegistrationIt has been registered in the PROSPERO database (CRD42018100254).

epidemiology↗